Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Qiagen NVQGEN -0.90%69 EV-to-EBITDA is 14.95 as of Aug. 05, 2026, which is 22% below its 10-year median of 19.27. GuruFocus rates QGEN with a GF Score™ of 69/100 and a GF Value™ of $52.73 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 119 Medical Diagnostics & Research companies, Qiagen NV ranks better than 55.46% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Qiagen NV's enterprise value is $9,652 Mil.
Qiagen NV's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was $646 Mil. Therefore, Qiagen NV's EV-to-EBITDA for today is 14.95.
The historical rank and industry rank for Qiagen NV's EV-to-EBITDA or its related term are showing as below:
QGEN'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 11.36 Med: 19.27 Max: 47.92
Current: 14.95
During the past 13 years, the highest EV-to-EBITDA of Qiagen NV was 47.92. The lowest was 11.36. And the median was 19.27.
QGEN's EV-to-EBITDA is ranked better than 55.46% of 119
companies
in the Medical Diagnostics & Research industry
Industry Median: 15.33
vs QGEN: 14.95
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Qiagen NV's share price for today is $41.95.
Qiagen NV's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.941.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Qiagen NV's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Qiagen NV's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Qiagen NV EV-to-EBITDA vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Qiagen NV's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Qiagen NV's EV-to-EBITDA falls into.
Qiagen NV's current Enterprise Value is $9,652 Mil.
Qiagen NV's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $646 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Qiagen NV (QGEN) has a EV-to-EBITDA of 14.95 as of Aug. 05, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Qiagen NV. This is 22% below median its historical median of 19.27. Over the past decade, Qiagen NV's EV-to-EBITDA has ranged from 11.36 to 47.92. According to the industry distribution chart, Qiagen NV ranks #53 out of 119 companies in the Medical Diagnostics & Research industry, placing it in the top 44.5%.
Is Qiagen NV's EV-to-EBITDA too high?
Qiagen NV's current EV-to-EBITDA of 14.95 is 22% below median its 10-year median of 19.27. Over the past 10 years, this metric has ranged from a low of 11.36 to a high of 47.92. The Medical Diagnostics & Research industry median EV-to-EBITDA is 15.33. Qiagen NV's value of 14.95 is 2.5% below this industry median. Based on the distribution chart, Qiagen NV ranks #53 out of 119 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Qiagen NV has a GF Score™ of 69/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Qiagen NV's EV-to-EBITDA compare to CRL and BLLN?
According to the Medical Diagnostics & Research industry distribution chart, Qiagen NV ranks #53 out of 119 companies for EV-to-EBITDA. This puts Qiagen NV in the upper half of its industry. The industry median EV-to-EBITDA is 15.33. Qiagen NV's value of 14.95 is 2.5% below this benchmark. Historically, Qiagen NV's own EV-to-EBITDA has ranged from 11.36 to 47.92 over the past decade. While the company's 10-year median is 19.27 vs. the industry median of 15.33, Qiagen NV has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Diagnostics & Research company?
The median EV-to-EBITDA among Medical Diagnostics & Research companies is 15.33, based on 119 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Qiagen NV's current EV-to-EBITDA of 14.95 is 2.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Qiagen NV. For the Medical Diagnostics & Research industry, the median EV-to-EBITDA is 15.33 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Qiagen NV's current EV-to-EBITDA is 14.95, which is 22% below median its own 10-year median of 19.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Qiagen NV stock overvalued right now?
Based on GuruFocus' analysis, Qiagen NV (QGEN) is currently considered Modestly Undervalued. The stock's GF Value™ is $52.73, compared to a current price of $41.95 — trading 20.4% below its estimated fair value. The current EV-to-EBITDA is 14.95, which is 22% below median its 10-year median of 19.27 and 2.5% below the Medical Diagnostics & Research industry median of 15.33. Qiagen NV's overall GF Score™ is 69/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Qiagen NV (QGEN), the current EV-to-EBITDA is 14.95 as of Aug. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Qiagen NV (QGEN) Overvalued in 2026?
Based on GuruFocus' analysis, Qiagen NV stock appears to be undervalued.
The current stock price of $41.95 is trading 20.4% below its estimated GF Value™ of $52.73.
GuruFocus considers Qiagen NV to be Modestly Undervalued.
Key valuation signals for QGEN:
EV-to-EBITDA: 14.95 (22% below median its 10-year median of 19.27)
GF Value™: $52.73 vs. price of $41.95 (20.4% below fair value)
Industry Position: 2.5% below the Medical Diagnostics & Research median (#53 of 119)
No single metric tells the full story. See the QGEN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2024 sales), followed by EMEA (33%), and the Asia-Pacific (15%).
69GF Score
Get the complete analysis for QGEN
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
QGEN has been successfully added to your 
